A Randomized Multicentre Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an
antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative
Breast Cancer (TNBC), and whose tumour cells make a protein called glycoprotein NMB (gpNMB),
which CDX-011 binds to. The study will also further characterize the safety of CDX-011
treatment in this patient population.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society